Search research articles
Contact Us
Filters
Showing results (11-20 of 76) with videos related to
Page
of 8
Sort By:
Kidney360
|
January 30, 2026
Impact of Kidney Histology and Choice of Treatment on Survival in Patients with Multiple Myeloma
David Klank, Julian Friedrich, Lina Rüsing, et al.
Acta Haematologica
|
June 5, 2004
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia
Martin C Müller, Tanja Hördt, Peter Paschka, et al.
Nucleic Acids Research
|
February 1, 2007
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
Zhongfa Liu, Shujun Liu, Zhiliang Xie, et al.
Haematologica
|
January 29, 2008
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Thomas Ernst, Philipp Erben, Martin C Müller, et al.
Cancer
|
March 5, 2005
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up
Tanja Lahaye, Birte Riehm, Ute Berger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
Andreas Neubauer, Kati Maharry, Krzysztof Mrózek, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 29, 2007
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
Shujun Liu, Rebecca B Klisovic, Tamara Vukosavljevic, et al.
Haematologica
|
April 12, 2005
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures
Lucy C Crossman, Motomi Mori, Yi-Ching Hsieh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2010
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
Peter Paschka, Richard F Schlenk, Verena I Gaidzik, et al.
Blood
|
July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
Andrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 76) with videos related to
Sort By:
Page
of 8
Kidney360
|
January 30, 2026
Impact of Kidney Histology and Choice of Treatment on Survival in Patients with Multiple Myeloma
David Klank, Julian Friedrich, Lina Rüsing, et al.
Acta Haematologica
|
June 5, 2004
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia
Martin C Müller, Tanja Hördt, Peter Paschka, et al.
Nucleic Acids Research
|
February 1, 2007
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
Zhongfa Liu, Shujun Liu, Zhiliang Xie, et al.
Haematologica
|
January 29, 2008
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Thomas Ernst, Philipp Erben, Martin C Müller, et al.
Cancer
|
March 5, 2005
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up
Tanja Lahaye, Birte Riehm, Ute Berger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
Andreas Neubauer, Kati Maharry, Krzysztof Mrózek, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 29, 2007
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
Shujun Liu, Rebecca B Klisovic, Tamara Vukosavljevic, et al.
Haematologica
|
April 12, 2005
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures
Lucy C Crossman, Motomi Mori, Yi-Ching Hsieh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2010
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
Peter Paschka, Richard F Schlenk, Verena I Gaidzik, et al.
Blood
|
July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
Andrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Page
of 8